Mineralys Therapeutics

MLYS · NASDAQ

$21.58+$0.66 (+3.15%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $20.92

Latest news

Press releaseOct 19, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Press releaseOct 9, 9:00 AM ETGlobe Newswire
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Press releaseOct 2, 4:30 PM ETGlobe Newswire
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Press releaseOct 1, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Press releaseSep 24, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Press releaseSep 23, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Press releaseAug 26, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Press releaseAug 11, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseAug 4, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
NewsJun 17, 1:35 PM ET
7 Health Care Stocks With Whale Alerts In Today's Session
Press releaseJun 14, 10:00 AM ETGlobe Newswire
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Press releaseJun 8, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseJun 8, 7:00 AM ETGlobe Newswire
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
NewsJun 3, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseJun 3, 6:00 AM ETGlobe Newswire
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Press releaseMay 30, 11:15 AM ETGlobe Newswire
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Press releaseMay 27, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMay 5, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Press releaseApr 29, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
Press releaseMar 12, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
NewsMar 12, 7:11 AM ET
Earnings Scheduled For March 12, 2026
Press releaseMar 9, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
Press releaseMar 3, 5:31 PM ETPRNewswire
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Press releaseNov 10, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 10, 6:12 AM ET
Earnings Scheduled For November 10, 2025
NewsNov 7, 10:03 AM ET
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Press releaseNov 5, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Press releaseNov 3, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
NewsSep 3, 8:17 AM ETAvi Kapoor
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsSep 2, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsSep 2, 10:16 AM ETAvi Kapoor
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
Press releaseAug 12, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NewsAug 12, 1:19 PM ETPiero Cingari
Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday?
NewsAug 12, 4:32 AM ET
Earnings Scheduled For August 12, 2025
NewsAug 11, 11:03 AM ET
Earnings Preview For Mineralys Therapeutics
Press releaseAug 4, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Press releaseJun 17, 7:00 AM ETGlobe Newswire
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
NewsMay 9, 3:01 PM ET
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Press releaseMay 7, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Press releaseMay 5, 4:05 PM ETGlobe Newswire
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
Press releaseMar 29, 2:30 PM ETGlobe Newswire
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
Press releaseMar 25, 8:00 AM ETGlobe Newswire
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
NewsMar 10, 1:09 PM ETAvi Kapoor
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
NewsMar 10, 7:29 AM ET
Market-Moving News for March 10th

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

7 Health Care Stocks With Whale Alerts In Today's Session

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

12 Health Care Stocks Moving In Wednesday's Intraday Session

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

Earnings Scheduled For May 6, 2026

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For March 12, 2026

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 10, 2025

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Nasdaq Down 1%; Signet Jewelers Earnings Top Views

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday?

Earnings Scheduled For August 12, 2025

Earnings Preview For Mineralys Therapeutics

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Market-Moving News for March 10th